Malformations of Cortical Development, Group I: Clinical Trials

154 trials for Malformations of Cortical Development, Group I, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

75 completed, 30 recruiting, 14 unknown, 13 active not recruiting. 39 Phase 2, 22 Not applicable, 20 Phase 3, 18 Phase 1, 6 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 239Completed 20, Recruiting 5, Active not recruiting 4, Unknown 4, Not yet recruiting 2, Terminated 2, Withdrawn 2
Not applicable22Completed 9, Unknown 5, Recruiting 3, Enrolling by invitation 2, Withdrawn 2, Active not recruiting 1
Phase 320Completed 12, Recruiting 3, Terminated 2, Active not recruiting 1, Unknown 1, Withdrawn 1
Phase 118Completed 11, Recruiting 4, Active not recruiting 2, Terminated 1
Phase 46Completed 4, Active not recruiting 1, Terminated 1

Follow Malformations of Cortical Development, Group I: new trials by email Literature Review of Malformations of Cortical Development, Group I trials Research Report on Malformations of Cortical Development, Group I

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neurocutaneous Syndromes in Children: Prevalence and Clinical Characteristics
Sturge-Weber Syndrome, Neurocutaneous Syndromes
Not yet recruitingAssiut University1002026-09-202026-09-28
Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)
AV078, Placebo - Tuberous Sclerosis Complex, Epilepsy
Phase 2Not yet recruitingAeovian Pharmaceuticals, Inc.422026-09-012026-09-29
Fluorescence Guided Focal Cortical Dysplasia Surgery
5-ALA (Gliolan) - Drug Resistant Epilepsy
Phase 2Not yet recruitingHospices Civils de Lyon52026-09-012026-06-18
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
SVG103 - Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC)
Phase 1 / Phase 2RecruitingSovargen122026-07-142026-08-10
Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)
Observational assessment - Periodontal Disease, Periodontitis
RecruitingStefan Lujinschi1002026-05-042026-06-26
A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines
Use of an electronic digital Application - Chronic Kidney Disease, Proteinuria
Not applicableRecruitingSt. James's Hospital, Ireland802026-01-142026-05-01
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Sapu003, Exemestane 25 MG - Breast Cancer Metastatic, Renal Cell Carcinoma (RCC)
Phase 1RecruitingSAPU NANO (US) LLC272025-12-152026-01-27
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk
Megalocephaly
Not yet recruitingAssistance Publique - Hôpitaux de Paris2002025-09-012025-08-27
TANDem-2: Closing the Gap to Interventions for TAND
Well-Beans for Caregivers Program - Adult Caregivers of Individuals With TSC, Tuberous Sclerosis Complex (TSC)
Not applicableEnrolling by invitationVrije Universiteit Brussel302025-07-152025-09-22
Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.
Radiprodil + co-administered drugs - Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia
Phase 1CompletedGRIN Therapeutics, Inc.182025-05-202025-11-18
Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults
Radiprodil with Carbamazepine, Radiprodil with Itraconazole - Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia
Phase 1TerminatedGRIN Therapeutics, Inc.302025-05-082025-11-21
Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy
MRI 3T and MRI 7T - Epilepsy, Drug Resistant Epilepsy
Not applicableRecruitingAssistance Publique - Hôpitaux de Paris202025-03-192025-03-21
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
Epidiolex 100 mg/mL Oral Solution - Lennox Gastaut Syndrome, Dravet Syndrome
Active not recruitingJazz Pharmaceuticals1112025-02-242026-06-03
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
Sertraline, Placebo - Neurodevelopmental Disorders, Autism
Phase 2RecruitingHolland Bloorview Kids Rehabilitation Hospital1302024-09-162026-07-27
Exploration and Evaluation of Amygdalo-Hippocampectomy According to Prof. Coubes' Technique: An Anatomical, Clinical, and Educational Approach
Amygdalo-Hippocampectomy - Hippocampal Sclerosis, Dysembryoplastic Neuroepithelial Tumor
RecruitingUniversity Hospital, Montpellier35042024-08-312025-04-08
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
Radiprodil - Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Phase 1 / Phase 2Active not recruitingGRIN Therapeutics, Inc.302024-07-102026-04-01
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
AAV9-hSyn1-miGRIK2 - Mesial Temporal Lobe Epilepsy
Phase 1 / Phase 2RecruitingUniQure Biopharma B.V.122024-06-122026-08-24
Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)
YCJ-01 Full Spectrum cannbis Extract, Placebo - Tuberous Sclerosis Complex (TSC)
Phase 3RecruitingOils4Cure842024-06-012026-02-11
First-in-human Experience Using Novel Ultraflexible Low-impedance Electrode Arrays: an IDEAL Stage 1 Study
Insertion of electrode during planned neurosurgery for epilepsy - Epilepsy, Focal Cortical Dysplasia
Not applicableUnknownGreat Ormond Street Hospital for Children NHS Foundation Trust62024-02-012023-11-03
Reproductive Options in Inherited Skin Diseases
Ichthyosis, Palmoplantar Keratoses
Enrolling by invitationMaastricht University Medical Center6502024-01-012025-05-18

Showing 20 of 154. Sign in to see all of them.

Narrower conditions

Tuberous Sclerosis (114)  ·  Epilepsy (34)  ·  Microcephaly (22)  ·  Seizures (18)  ·  Lymphangioleiomyomatosis (16)  ·  Autistic Disorder (12)  ·  Focal Cortical Dysplasia (12)  ·  Intellectual Disability (9)  ·  Epilepsies, Myoclonic (8)  ·  Hippocampal Sclerosis (8)  ·  Lennox Gastaut Syndrome (8)  ·  Angiomyolipoma (7)  ·  Drug Resistant Epilepsy (6)  ·  Megalencephaly (6)  ·  Zika Virus Infection (6)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (154)  ·  Nervous System Malformations (153)  ·  Nervous System Diseases (152)  ·  Malformations of Cortical Development (151)  ·  Congenital Abnormalities (150)  ·  Genetic Diseases, Inborn (119)  ·  Hamartoma (116)  ·  Neoplasms, Multiple Primary (116)  ·  Heredodegenerative Disorders, Nervous System (115)  ·  Neoplasms (115)  ·  Neoplastic Syndromes, Hereditary (115)  ·  Neurodegenerative Diseases (115)  ·  Neurocutaneous Syndromes (111)  ·  Central Nervous System Diseases (50)

Interventions

Everolimus (18)  ·  Sirolimus (15)  ·  Cannabidiol (6)  ·  Activator Appliances (3)  ·  Vigabatrin (3)  ·  ganaxolone (3)  ·  radiprodil (3)  ·  Anticonvulsants (2)  ·  Melatonin (2)  ·  Urination (2)  ·  2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine (1)  ·  Acceptance and Commitment Therapy (1)  ·  Actigraphy (1)  ·  Aspirin (1)  ·  Betaine (1)

Sponsors

Children's Hospital Medical Center, Cincinnati (7)  ·  Jazz Pharmaceuticals (6)  ·  Novartis Pharmaceuticals (6)  ·  University of California, Los Angeles (6)  ·  National Heart, Lung, and Blood Institute (NHLBI) (5)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Beijing Children's Hospital (3)  ·  Boston Children's Hospital (3)  ·  GRIN Therapeutics, Inc. (3)  ·  Institut National de la Santé Et de la Recherche Médicale, France (3)  ·  Longboard Pharmaceuticals (3)  ·  Marinus Pharmaceuticals (3)  ·  Nobelpharma (3)  ·  Cardiff University (2)  ·  Dana-Farber Cancer Institute (2)

Countries

United States (76)  ·  France (22)  ·  Australia (17)  ·  United Kingdom (17)  ·  Canada (13)  ·  China (12)  ·  Italy (12)  ·  Netherlands (12)  ·  Spain (12)  ·  Poland (11)  ·  Belgium (6)  ·  Germany (6)  ·  Japan (6)  ·  Brazil (5)  ·  Israel (5)

Top investigators

Darcy Krueger, MD, PhD (3)  ·  Joel Moss, M.D. (3)  ·  Anna Jansen, MD, PhD (2)  ·  Antoni Gostynski, MD, PhD (2)  ·  Dennis J Dlugos, MD (2)  ·  Hope Northrup, MD (2)  ·  John Bissler, MD (2)  ·  Martina Bebin, MD, MPA (2)  ·  Mary Kay Koenig, MD (2)  ·  Mustafa Sahin, MD, PhD (2)  ·  Alessandra Pereira,, PhD, MD (1)  ·  Alessandro Flavio Ferri (1)

Results publications

PMID 29023494, PMID 30053159, PMID 30291925, PMID 31912454, PMID 34957550, PMID 38996393, PMID 18184959, PMID 19141364, PMID 21047224, PMID 21482669, PMID 21525172, PMID 21915260, PMID 22002941, PMID 22113127, PMID 22262746, PMID 22396514, PMID 22934754, PMID 23158522, PMID 23325902, PMID 23437092, PMID 23732715, PMID 23733802, PMID 23798472, PMID 24729041, PMID 25456370, PMID 25682485, PMID 26156073, PMID 26381530, PMID 26858193, PMID 27222591, PMID 27351628, PMID 28431241, PMID 28715527, PMID 28877754, PMID 29096777, PMID 29258560, PMID 29539287, PMID 29572283, PMID 29797247, PMID 29800026, PMID 29800048, PMID 29899452, PMID 30192751, PMID 30424962, PMID 31217257, PMID 31237569, PMID 31444548, PMID 31640736, PMID 31969108, PMID 31982581

NIH funding

2015 (2), 2018 (2), 2023 (2), 2025 (2), U54NS092090 (2), 2008 (1), P30CA006516 (1), R01AG061111 (1), R01CA107164 (1), R01HD090138 (1), R21CA103486 (1), U01HG006487 (1), U01NS082320 (1), U01NS092595 (1), UL1RR024989 (1)